Health Care & Life Sciences » Pharmaceuticals | Adamas Pharmaceuticals Inc.

Adamas Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
50,921.00
10,223.00
51,802.00
60,058.00
89,490.00
130,999
Depreciation, Depletion & Amortization
66.00
155.00
435.00
808.00
1,194.00
1,460
Other Funds
-
1,761.00
-
-
-
35,070
Funds from Operations
56,206.00
15,715.00
40,536.00
48,980.00
70,122.00
94,469
Changes in Working Capital
29,405.00
10,479.00
6,674.00
912.00
3,295.00
9,754
Net Operating Cash Flow
26,801.00
26,194.00
47,210.00
48,068.00
66,827.00
104,223
Capital Expenditures
167.00
1,285.00
1,399.00
1,624.00
1,258.00
Purchase/Sale of Investments
-
96,095.00
9,457.00
25,085.00
26,823.00
Net Investing Cash Flow
167.00
97,380.00
8,058.00
26,709.00
25,565.00
Issuance/Reduction of Debt, Net
4,000.00
-
-
-
98,967.00
Net Financing Cash Flow
3,979.00
47,020.00
10,810.00
65,408.00
108,843.00
Net Change in Cash
22,655.00
24,166.00
28,342.00
9,369.00
67,581.00
Free Cash Flow
26,634.00
24,909.00
48,609.00
49,692.00
68,085.00
Change in Capital Stock
21.00
45,259.00
10,810.00
65,408.00
9,876.00

About Adamas Pharmaceuticals

View Profile
Address
1900 Powell Street
Emeryville California 94608
United States
Employees -
Website http://www.adamaspharma.com
Updated 07/08/2019
Adamas Pharmaceuticals, Inc. is a pharmaceutical company, which engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products includes ADS-5012, ADS-4101, and Namenda XR. The ADS-5102 is a treatment for levodopa-induced dyskinesia in patients with Parkinson's disease.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.